Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 2
2021 1
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
Smit MJ, Sander AF, Ariaans MBPA, Fougeroux C, Heinzel C, Fendel R, Esen M, Kremsner PG, Ter Heine R, Wertheim HF, Idorn M, Paludan SR, Underwood AP, Binderup A, Ramirez S, Bukh J, Soegaard M, Erdogan SM, Gustavsson T, Clemmensen S, Theander TG, Salanti A, Hamborg M, de Jongh WA, McCall MBB, Nielsen MA, Mordmüller BG; COUGH-1 trial study group. Smit MJ, et al. Among authors: underwood ap. Lancet Microbe. 2023 Mar;4(3):e140-e148. doi: 10.1016/S2666-5247(22)00337-8. Epub 2023 Jan 18. Lancet Microbe. 2023. PMID: 36681093 Free PMC article. Clinical Trial.
B cell characteristics define HCV reinfection outcome.
Underwood AP, Gupta M, Wu BR, Eltahla AA, Boo I, Wang JJ, Agapiou D, Abayasingam A, Reynaldi A, Keoshkerian E, Zhao Y, Brasher N, Walker MR, Bukh J, Maher L, Gordon T, Davenport MP, Luciani F, Drummer HE, Lloyd AR, Bull RA. Underwood AP, et al. J Hepatol. 2024 Apr 9:S0168-8278(24)00271-X. doi: 10.1016/j.jhep.2024.04.004. Online ahead of print. J Hepatol. 2024. PMID: 38604387 Free article.
Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination.
Underwood AP, Sølund C, Fernandez-Antunez C, Villadsen SL, Mikkelsen LS, Fahnøe U, Bollerup S, Winckelmann AA, Schneider UV, Binderup A, Vizgirda G, Sørensen AL, Vinten CN, Dalegaard MI, Ramirez S, Weis N, Bukh J. Underwood AP, et al. EBioMedicine. 2023 Mar;89:104475. doi: 10.1016/j.ebiom.2023.104475. Epub 2023 Mar 2. EBioMedicine. 2023. PMID: 36870117 Free PMC article.
Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines.
Sølund C, Underwood AP, Fernandez-Antunez C, Bollerup S, Mikkelsen LS, Villadsen SL, Fahnøe U, Winckelmann AA, Feng S, Nørløv Vinten CA, Dalegaard MI, Vizgirda G, Sørensen AL, Ramirez S, Bukh J, Weis N. Sølund C, et al. Among authors: underwood ap. Vaccines (Basel). 2022 Jan 4;10(1):75. doi: 10.3390/vaccines10010075. Vaccines (Basel). 2022. PMID: 35062736 Free PMC article.
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
Underwood AP, Sølund C, Fernandez-Antunez C, Villadsen SL, Winckelmann AA, Bollerup S, Mikkelsen LS, Sørensen AL, Feng S, Fahnøe U, Lassauniere R, Fomsgaard A, Ramirez S, Weis N, Bukh J. Underwood AP, et al. EBioMedicine. 2021 Sep;71:103519. doi: 10.1016/j.ebiom.2021.103519. Epub 2021 Aug 19. EBioMedicine. 2021. PMID: 34419923 Free PMC article.
Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2.
Underwood AP, Sølund C, Jacobsen K, Binderup A, Fernandez-Antunez C, Mikkelsen LS, Inekci D, Villadsen SL, Castruita JAS, Pinholt M, Fahnøe U, Ramirez S, Brix L, Weis N, Bukh J. Underwood AP, et al. Front Immunol. 2024 Mar 20;15:1353353. doi: 10.3389/fimmu.2024.1353353. eCollection 2024. Front Immunol. 2024. PMID: 38571939 Free PMC article.